Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.61 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.52 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4347459 | 0.86 | GRM5 (0.63) | GRM5TRPV4 | |
| SCHEMBL990305 | 0.81 | GRM5 (0.62) | GRM5TRPV4 | |
| SCHEMBL992311 | 0.78 | GRM5 (0.72) | GRM5 | |
| SCHEMBL990232 | 0.76 | GRM5 (0.77) | GRM5 | |
| SCHEMBL991476 | 0.76 | GRM5 (1.00) | GRM5 | |
| SCHEMBL990839 | 0.75 | GRM5 (1.00) | GRM5 | |
| SCHEMBL12425612 | 0.74 | VNN1 (0.50) | TRPV4VNN1 | |
| SCHEMBL990229 | 0.73 | GRM5 (0.74) | GRM5 | |
| SCHEMBL11563504 | 0.73 | HCAR3 (0.73) | GRM5 | |
| SCHEMBL990086 | 0.73 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | claimed |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | GRM5 1/4885TRPV4 706/4885VNN1 4472/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885TRPV4 724/4885VNN1 4561/4885 |
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | GRM5 680/4885TRPV4 758/4885VNN1 178/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GRM5 1/4885TRPV4 724/4885VNN1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.